Use of electronic medical records and biomarkers to manage risk and resource efficiencies. by Ryan, Dermot et al.
Use of electronic medical records and biomarkers to manage risk and resource
efficiencies
Dermot Ryan a, John Blakeye, Alison Chisholmb, David Priceb,c,d, Mike Thomasf, Björn Ställbergg,
Karin Lisspersg, Janwillem W. H. Kocks h and on behalf of the Respiratory Effectiveness Group
aUsher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK; bRespiratory Effectiveness Group,
Cambridge, UK; cCentre for Academic Primary Care, University of Aberdeen, Aberdeen, UK; dObservational and Pragmatic Research Institute,
Singapore; eClinical Sciences, Liverpool School of Tropical Medicine, and Respiratory Medicine, Royal Liverpool Hospital, Liverpool, UK;
fPrimary Care and Population Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; gDepartment of Public Health
and Caring Science, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; hDepartment of General Practice and
Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, Groningen, the
Netherlands
ABSTRACT
The migration from paper to electronic medical records (EMRs) was motivated by the adminis-
trative need to record, retrieve and process increasing amounts of clinical data in the 1980s. In
the intervening period, there has been growing recognition of the potential of such records for
achieving care efficiencies, informing clinical decision making and real-life research. EMRs can be
used to characterise patient groups, management approaches and differential outcomes.
Characterisation can also help with identification of potential biomarkers for future risk determi-
nation and likely treatment response. The future heralds even greater opportunities through
integration of clinical records and a range of technology-based solutions within a more complete
electronic health record (EHR). Through application of algorithms based on identified risk pre-
dictors and disease determinants, clinical records could also be used to enable risk stratification
of patients to optimise targeted interventions, conserving resources to achieve individual patient
and system-wide benefit. In this review, we reflect on the evolution of the EMR and EHR and
discuss current and emerging opportunities, particularly with respect to biomarkers and targeting
of innovative biologic interventions. We also consider some of the critical issues associated with
realising the potential of the EHR as a clinical aid and research tool in an age of emerging
technologies.
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The origins of electronic medical records
Electronic medical records (EMRs) were first intro-
duced in the 1980s, motivated by the need for more
sophisticated data management in the face of ever
more (and more complex) medical information.[1,2]
The increasing volume of clinical and laboratory data
available required the development of an infrastructure
that facilitated data capture, storage and searchability.
In parallel, escalating healthcare costs required clinical
events to be time- and date-stamped using standar-
dised disease and drug coding hierarchies to facilitate
reimbursement administration and to track healthcare
utilisation and budgets.
The pace of transition from paper to electronic
medical records differed between countries, led by
more developed healthcare systems but also cata-
lysed by regulation and/or financial incentives. In
the USA, a 2014 federal mandate required all public
and private healthcare providers and other eligible
professionals to adopt and demonstrate ‘meaningful
use’ of EMRs in order to maintain their existing
Medicaid and Medicare reimbursement levels.[3]
‘Meaningful use’ was targeted at their potential to
improve healthcare quality, safety, efficiency and
coordination, and patient and family engagement
with a view to reducing healthcare disparities and
improving public health. Although not so expressly
mandated elsewhere, early government incentives
around EMRs saw rapid, widespread adoption in
the UK and an ostensibly ‘paper-free’ approach to
clinical data recording within primary care by the
turn of the millennium. Although there was no
financial incentive attached, EMRs were also
adopted early in Sweden; implemented within pri-
mary care in the mid-1990s and in secondary care
at the turn of the millennium.
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Where the migration from paper to electronic med-
ical records has occurred, EMRs have not only pro-
vided a more efficient means of recording patient data
and an improved infrastructure for billing, they have
also provided unprecedented opportunities to improve
clinical management and for clinical research.
Current use – clinical management and
resource efficiencies
Electronic medical records contain a wide range of
structured, routinely recorded care clinical and demo-
graphic data that can be used to improve understanding
of population and disease profiles and of current prac-
tice. Characterisation can be applied to individual prac-
tices or more broadly: at the regional, national or even
international level. Cross-sectional analysis of EMRs can
help to quantify and characterise disease course and
prevalence, healthcare resource use and routine care
management approaches (e.g. service audit and evalua-
tion of guideline implementation). Such data can assist
with effective, efficient resource planning and care pro-
vision by providing a baseline against which change can
be measured. They also provide the opportunity to
identify examples of both optimal and suboptimal prac-
tice and over- and under-resourcing, which can help to
predict and mitigate against future system pressures and
shortfalls in care.[4,6]
Longitudinal analysis of EMRs can be used to
further characterise care pathways (e.g. patients’ diag-
nostic journeys) [7], disease progression and to evalu-
ate the (comparative) safety and effectiveness of
interventions. Comparative effectiveness studies using
routine care data offers a means of evaluating real-life
treatment outcomes and differential treatment
responses across patient subpopulations as a comple-
ment to idealised clinical trial efficacy outcomes.[5]
The creation of these very large datasets coupled
with the increasing capability of machine learning
approaches could be used to develop dynamic clinical
decision support systems (CDSS) to optimise clinical
benefit and minimise patient risk. In the Netherlands,
the majority of EMRs incorporate a decision support
tool developed in collaboration with the Dutch
College of General Practitioners. It has been rolled
out across a range of chronic disease areas since
2009 and is widely accepted by general practitioners
and practice nurses.[8] A recent evaluation of the
system, however, found that although the CDSS is
positively viewed it has limited impact on clinicians’
behaviour. When questioned about the reasons for
their low implementation of the system’s care recom-
mendations, user feedback revealed a lack of aware-
ness of the system’s functionality, limited belief in its
relevance and value and perceived challenges in inte-
grating the recommendations into daily practice.[9]
These barriers to uptake are the cautionary counter
to the potential of the EMR: in order to realise the
potential of EMR-based CDSS, there is a need for
clear planning and co-design with healthcare profes-
sionals to ensure they are valuable and practical tools.
Emerging opportunities: risk reduction and
biomarkers
Beyond their potential for general patient and practice
characterisation, there has also been a growing trend to
use EMRs (Figure 1) to identify ‘at-risk’ clinical prac-
tices and patient characteristics.[10–12] Interrogation
of EMRs has also revealed the potential value of routi-
nely recorded data to identify and validate the use of
existing and exploratory biomarkers (e.g. blood eosi-
nophils, FeNO [existing]; exhaled breath condensate
markers [proposed]).[13] The integration of biomarker
and existing clinical data may help to tailor diagnostic
and management decisions to individual patients and
their needs and to develop a more dynamic and
responsive CDSS.
Risk 
Identification
Incorrect
diagnosis 
Appropriate
medication
prescribing
Guideline 
recommended
or not
Appropriate
medication use^
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Erratic 
non-
adherence*
Intelligent 
non-
adherence*
Other 
medications 
e.g. 
selective
beta 
blockers 
Contributory 
factors 
Smoking Comorbidities,e.g. rhinitis 
Other 
Phenotypes Biomarkers 
Figure 1. Variables available within routine primary care EMRs that can be used to explore future risk in respiratory disease. Notes:
^Inhaler technique/handling errors are also important, but device issues are not routinely captured in primary care records. *World
Health Organization (WHO) adherence categories.[14]
2 D. RYAN ET AL.
Biomarkers within obstructive airways disease
diagnosis
In the absence of a single diagnostic test for asthma,
diagnosis involves a combination of clinical assessment
(history taking, objective measurements) and ‘clinical
judgment’.[15] The more clinical evidence available, the
more accurate the diagnostic accuracy and better
informed the selection of treatment options. By contrast
the diagnosis of COPD is defined by the presence of a
threshold level of airway obstruction in conjunction with
characteristic symptoms.[16] Disease features (e.g. symp-
tom scores and exacerbation frequency) have been intro-
duced as additional dimensions to help guide and direct
COPD therapy.[17] Thus routinely recorded biomarkers
– objectively measured and evaluated characteristics that
can indicate normal biological or pathogenic processes
and/or potential response to a pharmacological interven-
tion [18] – may hold the potential to further support
diagnostic and optimum therapeutic decision making.
Almost a dozen potential biomarkers have (so far)
been proposed in asthma; see Table 1.[19,20] Nine of
the biomarkers currently proposed are potentially
viable for evaluation in observational studies, but only
three via retrospective observational studies using rou-
tinely collected primary care EMRs. These are: com-
plete blood counts (CBC), particularly blood eosinophil
count, fractional exhaled nitric oxide (FeNO), and
total/allergen-specific immunoglobulin E (IgE).
Eosinophils
Complete blood counts provide a clear example of the
potential for biomarker identification and patient risk
profiling using routinely recorded EMRs.
Asthma is a condition frequently driven by eosi-
nophilic airways inflammation.[21] The extent of
eosinophillic inflammation present in patients with
asthma can be detected in a variety of ways, among
them induced sputum analysis. Raised sputum eosi-
nophil count (sputum eosinophilia) has been identi-
fied as a marker of future asthma risk, with studies
suggesting that sequential sputum eosinophil assess-
ment could be used as a model for managing patient
care.[22] Yet the technical skill involved in sputum
induction and analysis are barriers to its use in rou-
tine care. Blood eosinophils, in contrast, are relatively
easy and inexpensive to assess in primary care.
Indeed, as blood tests are used in primary care for
a number of reasons (e.g. often as a means of general
exploratory investigation in response to reported fati-
gue) CBC and blood eosinophil data are present in a
large number of patients’ records. Not only are blood
eosinophils relatively easy to evaluate, they also
appear to correlate well with sputum eosinophilia
[23] and to be responsive to inhaled corticosteroid
(ICS) therapy.[24] In addition, an observational study
using routine care EMRs concluded that UK patients
with asthma and blood eosinophil counts greater
than 400 cells per μl experience more severe exacer-
bations and have poorer asthma control than those
with lower blood eosinophil counts and reported a
count–response relationship between blood eosino-
phil counts and asthma-related outcomes.[11]
Similar to the dose ranging efficacy and safety with
mepolizumab in severe asthma (DREAM) study,[12]
there was a clear association seen between increasing
eosinophil count and both poorer asthma control and
higher rates of exacerbation. Thus there is compelling
Table 1. List of biomarkers of potential use in asthma; those in bold are the most likely candidates for interrogation using routine
care EMRs.
Characterisation of study populations for prospective clinical trials
(i.e. baseline information)
Prospective clinical trial efficacy/
effectiveness outcomes
Observational study
outcomes*
Core outcomes Serologic multi-allergen screen (IgE) to define atopic status
(also for observational studies)
None None
Supplemental
outcomes
Feno Feno Feno
Sputum Sputum Sputum
CBC (total eosinophils) CBC (total eosinophils) CBC (total eosinophils)
Total IgE Total IgE Total IgE
Allergen-specific IgE Allergen-specific IgE Allergen-specific IgE
Urinary LTE4 Urinary LTE4 Urinary LTE4
Emerging
outcomes
Allergen skin prick testing Allergen skin prick testing
Sputum neutrophils and analyses Sputum neutrophils and analyses Sputum neutrophils and
analyses
Airway imaging Airway imaging Airway imaging
Exhaled breath condensate markers Exhaled breath condensate markers
Discovery through genetics and genomics Discovery through genetics and
genomics
Discovery through genetics
and genomics
*Observational study designs include cohort, case-control, cross-sectional, retrospective reviews; genome-wide association studies (GWAS) and secondary
analysis of existing data. Some measures may not be available in studies using previously collected data.
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evidence to suggest blood eosinophilia may predict
response to ICS therapy in asthma, but currently
insufficient data available to inform dose- and
count-specific recommendations.
In COPD, interest in eosinophil count as a poten-
tial biomarker has centred on its potential to predict
ICS treatment response and reduce ICS over treat-
ment in a disease that is ostensibly unresponsive to
steroid treatment.[25] Recent studies suggest that ICS
withdrawal may be a safe and effective strategy in
COPD,[26] but there is a belief that a significant
number of patients may derive some degree of ben-
efit from ICS.[27] Thus tools are required to help
differentiate such patients from those who may ben-
efit from steroid tapering strategies. As evidence of
eosinophil presence in the airways indicates the pre-
sence of steroid-responsive disease, confirmatory per-
ipheral markers such as elevated blood eosinophils
may help identify patients who could benefit from
steroid treatment. There are now analyses that sup-
port this approach,[28,29] but a widely accessible and
affordable point-of-care tool to identify COPD
patients with eosinophilic inflammation with a view
to informing management approaches remains a
future aspiration and more likely the preserve of
specialist care in the short term.
Fractional exhaled nitric oxide
Recent evidence suggests FeNO may be a suitable alter-
native to blood eosinophils in identifying pulmonary
eosinophilic inflammation in adults,[30] as it offers the
potential to inform the diagnosis and management of
obstructive lung disease, most notably asthma.[31,32]
FeNO offers the benefit of being a non-invasive and
reproducible assessment that can be easily carried out
in primary care (in minutes) using hand-held meters,
although there are some limitations when used in
patients who smoke.[33] EMR studies have largely
been thwarted by poor uptake of FeNO assessment in
clinical practice. This may reflect a lack of understand-
ing of its potential utility and financial concerns
around upfront cost of FeNO machines and/or a lack
of universal reimbursement despite evidence demon-
strating its affordability in a routine primary care set-
ting.[34]
The American Thoracic Society [35] offers guidance
for the interpretation and clinical use of FeNO, out-
lining low (≤25 ppb) and high (≥50 ppb) thresholds
below which inflammatory airways disease can be ruled
out and above which eosinophilic inflammation is
likely. Where further guidance is required, particularly
in the intermediate range (26–49 ppb), there may be
value in combining FeNO readings with clinical
symptom scores to help substantiate a diagnosis of
asthma, particularly to ‘rule-in’ asthma in the primary
care environment (see Figure 2).[36]
The most recent Cochrane review on the use of
FeNo recommends its selective use in patients who
have frequent asthma exacerbations.[37] Yet the related
literature is evolving rapidly and clear guidance is still
awaited on the optimal use of FeNO as a practical tool
in wider asthma management.[38–40] The real-life case
studies featured in Figure 3 provide some examples of
how FeNO could be used to guide asthma diagnosis
and subsequent assessment and monitoring within
routine primary care.
Within COPD, the role of FeNO as a clinical man-
agement tool is less well explored, but there are pre-
liminary data to suggest intermediate (>25 ppb) and
high (>50 ppb) levels of FeNO could aid in the identi-
fication of patients with a mixed asthma-COPD phe-
notype.[41]
Serum immunoglubulin e (IgE)
IgE has to date infrequently been assessed in primary
care, limiting opportunities to use EMR to explore the
potential of total and specific IgE (SIgE) measurements.
The SIgE landscape may be on the verge of change,
however: the Dutch national asthma guidelines have
recently recommended SIgE assessment to be con-
ducted in all patients with suspected allergies, which
will result in an inevitable increase in data points and
research opportunities.[42]
Figure 2. Receiver operating characteristic curves of fractional
exhaled nitric oxide and clinical signs and symptoms. Adding
clinical symptom scores to FeNO can help to confirm asthma in
patients for whom the AUC is significantly shifted to the left.
Reproduced from BJM Open, Schneider A, Wagenpfeil G, Jörres
RA, Wagenpfeil S. 5:e009676, 2015 with permission from BMJ
Publishing Group Ltd.[36]
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Case 1. Using FeNO as an acute asthma management tool.
     A 24-year-old woman with long-term asthma, well controlled using single maintenance and reliever therapy
(SMART) therapy presents. She has had a severe cough with some thick tenacious sputum for five days,
commencing with a short, febrile illness. The cough comes in bouts and is disturbing her sleep and is
accompanied by retrosternal pain.
     On examination, she is visibly upset and somewhat tearful. Pulse 80 bpm, regular; no fever. Lung fields clear
on auscultation. Respiratory rate normal. She is unable to perform a peak expiratory flow measurement as forced
expiration caused her to have spasms of coughing. However a FeNO test was performed with no difficulty,
resulting in a reading of 15 ppb, suggesting there was no eosinophilic inflammation responsible for her symptoms.
     A diagnosis of acute tracheitis was made. Oral steroids were judged to be unnecessary. The nature and
duration of the illness were explained to her with a warning that these symptoms would continue for some
four-to-six weeks with slow but gradual improvement but to re-attend if symptoms deteriorated.
     In this situation, FeNO testing avoided use of oral corticosteroids by informing the clinician that the
patients’ symptoms were not due to a deterioration in her asthma.
Case 2. Use of FeNO for assessment and management.
      A 45-year-old man, who was previously well, with no history of any chronic disorder, presented at the clinic
with marked shortness of breath and wheezing, which had commenced over the previous 36 h. He was a
non-smoker. There was no history of any infectious disorder.
      Clinical assessment revealed a man who was able to complete sentences. His pulse rate was 110 bpm,
regular and his respiratory rate was 22 breaths per minute. Examination of his chest revealed widespread
high-pitched expiratory wheeze. His peak flow reading was 340 l min–1 (predicted 620 l min–1). He was
administered four puffs of salbutamol through a spacer device and his peak flow was rechecked a few minutes
later when it had risen to 410 l min–1. His respiratory rate had slowed to 18 breaths a minute.
      A diagnosis of acute asthma attack was made. He was commenced on prednisolone 40 mg day–1 for 7 days.
Inhaled corticosteroids were also commenced and clear instructions as to the use of salbutamol on an as-needed
basis. He was given a peak flow meter and asked to record his readings twice daily. An appointment was made
for review the following morning.
      The following morning he showed considerable improvement, having slept almost undisturbed. His respiratory
rate was 15 breaths per minute, peak flow 500 l min–1 and his chest revealed some scattered expiratory wheeze.
A review appointment was made for the following week, having received information and advice as to when to
seek urgent advice should things deteriorate in the meantime.
      At one week, there was further improvement. He had no night symptoms but was still breathless on exertion.
His chest was clear and his peak flow reading had risen to 600 l min–1. After further education and
self-management a further review appointment was made to review his status after a month of ICS treatment.
Inhaler technique was assessed and perfected.
      One month later, at review, there was no further improvement with prominent exertion-related symptoms.
The serial peak flow readings revealed a diurnal variability of 70 l min–1. A decision was made to add a LABA to
his existing prescription of budesonide 400 µg twice daily so a prescription for budesonide 200 µg/formoterol 6
µg, two puffs twice daily was issued with an appointment for further review in four weeks.
      At review there was little alteration. The patient assured the doctor that the medication was being taken as
prescribed with the occasional missed dose because of forgetfulness. A FeNO measurement was taken revealing
a reading of 123 ppb, suggesting either poor compliance or continued eosinophilic inflammation. The ICS was
increased to a total of 1,600 µg per day and a further review arranged for four weeks. At this review the patient
was completely asymptomatic. His peak flow readings had risen consistently for the first three weeks following his
previous review, levelling out at 790 l min–1 with diurnal variation of around 40 l min–1. A decision was made to
continue at this level of medication and review in three months with a view to gradually stepping down the dose
of ICS.
      In this instance the use of peak flow monitoring gave false reassurance that optimal lung function
had been attained. The addition of FeNO added a piece of information which permitted a slightly different
strategy that, ultimately, resulted in achieving symptomatic control.
Figure 3. Illustrative case examples of how FeNO and blood eosinophils can be used alone, or in combination, to guide diagnostic
and clinical decision making in routine primary care. They are drawn directly from UK clinical practice and are not intended to
suggest a paradigm of clinical perfection, but serve to exemplify the use of evidence applied to an individual patient’s clinical need.
The cases have been abbreviated and simplified to maintain patient confidentiality (without adaptation of the clinical content).
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The recent American Academy and American College
of Asthma, Allergy and Immunology joint statement on
allergy testing notes the limited contribution of total
serum IgE estimation to allergy diagnosis.[43] The joint
statement also advises that interpretation of specific IgE,
as with skin tests, requires correlation with the history,
physical examination, and, in some cases, symptoms
directly observed after exposure to allergens, a view
shared by the European Academy of Allergy and
Clinical Immunology.[44] The true value of specific IgE
as a potential biomarker, or possible proxy for care qual-
ity,[44] awaits evolution of the single-system EMR to
more complete electronic health recording that integrates
data from a range of clinical and environmental sources.
The increasing number of specific IgE data points col-
lected in the Netherlands may offer a means of confirm-
ing the utility of this approach.
Combined biomarkers
As with all clinical approaches, improved understand-
ing of the clinical situation is achieved by piecing
together different information sources and integrating
complementary data. While routinely captured biomar-
kers can be used in isolation to predict future exacer-
bation risk, they can also be used in combination with
other routinely collected data to create more powerful,
composite metrics for predicting future risk.
[12,45,46, 47]
In addition, there is the potential promise of greater
clinical insight through combining FeNO and blood
eosinophil values to generate a ‘composite inflammatory
biomarker’. Both are markers of local and systemic
eosinophilic inflammation and both are elevated in
patients with asthma.[47–49] Using data from the
National Health and Nutrition Examination Survey
(NHANES) cohort, Malinovschi et al. explored the asso-
ciations between blood eosinophil and wheeze, asthma
diagnosis, and asthma events and between FeNO and
wheeze, asthma diagnosis and events in a random sam-
ple of more than 12,000 patients.[50] Elevated (inter-
mediate or high) FeNO values and intermediate or high
blood eosinophil values were independently associated
with all three outcomes. This independent association
with wheeze, asthma diagnosis and asthma events sug-
gests that FeNO and blood eosinophils may measure
different aspects of inflammation (both local and sys-
temic) and that their use in combination could improve
phenotyping in patients with asthma.
Further work is required to establish the additive
benefit of combining FeNO with blood eosinophils in
higher-step asthma patients. Questions persist as to
whether raised FeNO and blood eosinophil count
may be markers of a persistent inflammatory pheno-
type that does not respond to ICS therapy and whether
they could be used to identify patients who will benefit
from specialist referral and possible biological therapy.
The role of retrospective EMRs in the validation of
these findings is currently limited by the dearth of
FeNO data in routine care records, but existing EMRs
could be used to identify patients with complete blood
eosinophil records for prospective FeNO data collec-
tion. Supplementation of routine care EMRs with pro-
spectively collected FeNO data could be a feasible and
low-cost approach to further investigating blood eosi-
nophil levels and FeNO as a composite biomarker in
the diagnosis and management of asthma. Figure 3,
Case 3. Using combined FeNO and blood eosinophils to aid asthma diagnosis.
      A 35-year-old man presented at the general practice with a week-long history of itchy nose, itchy eyes and
sneezing which for the last three days were accompanied by wheezing with a sensation of breathlessness and
tight chested on exertion. He was a non-smoker. He had previously been healthy but did recount that he had
been a chesty child.
      Physical examination revealed: pulse rate 90 bpm, regular. Respiratory rate 18. Auscultation revealed
widespread expiratory wheeze. A peak flow reading (best of three) delivered a result of 440 l min–1. Two puffs
of salbutamol were administered via a spacer device and the peak flow rechecked after 4 min. This had risen to
550 l min–1. There was now no wheezing in the chest on further auscultation.
      Searching through the notes, a full blood count had been performed the previous year for an insurance
medical examination revealing an eosinophil count of 410 mm3 A FeNO measurement was also taken, giving a
reading of 84 ppb.
      The combination of symptoms, significant airway reversibility, an elevated peripheral
eosinophil count coupled with an elevated FeNO suggested an asthma diagnosis was likely.
Treatment with an appropriate dose of inhaled corticosteroids was commenced.
Figure 3. Continued.
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case 3 illustrates how the UK authors of this paper have
utilised FeNO and eosinophil data in combination, to
guide clinical decision making in their own practice
settings.
Other potential candidates for composite asthma
biomarkers include total serum IgE and blood eosi-
nophils to predict response to omalizumab. A post-
hoc analysis of the INNOVATE Trial [51] examined
the impact of omalizumab treatment (vs. placebo) on
exacerbation rates and health-related quality of life in
patients with severe allergic asthma (SAA), stratified
by peripheral blood eosinophils and serum IgE.[52]
The investigators concluded that patient subgroups
with a combination of increased serum IgE and
blood eosinophils might experience greater clinical
benefit. Pooling routine EMRs at a national (and
even international) level could help to generate
hypotheses and to power further exploratory studies
in SAA, such as to test the hypothesis that combining
serum IgE with blood eosinophils may offer addi-
tional benefit in identifying patients with a mixed
asthma-COPD.[53,54]
The future of EHRs
The preceding sections have largely discussed the ana-
lysis potential of EMRs gathered and reported in a
single setting such as primary care. Many systems
now incorporate an ability to share information
between providers – a move toward genuinely more
extensive, integrated electronic health records (EHRs).
[55] A more complete picture of an individual’s health
requires additional information than can be manually
entered by clinicians during brief consultations. The
next stage of development for EHRs is the routine
incorporation of data from connected devices.
The exponential increase in available processing
power and accompanying reduction in the size and
cost of sensor technology has brought about a formid-
able change in the use of everyday items, most notably
mobile telephones. In this context, there are now ‘smart’
versions of many common inhalers and of peak flow
meters and spirometers. These innovations permit real-
time assessment of medication use (concordance and
beta-agonist consumption) and inhaler technique. Such
data can be placed in the context of combining a fine-
grain symptom record, incorporating peak flow read-
ings, location and activity, environmental data such as
pollen count [56] or pollution levels, ultimately validat-
ing their inclusion or exclusion within a CDSS.
Introducing data from such systems into the EHR
offers the potential for semi-automated standard action
plans, via a CDSS, reducing the risk of inappropriate
treatment. Relevant healthcare advice (such as inhaler
technique guidance) could be offered through a perso-
nalised interface such as an integrated mobile phone
app. Clinicians may favour using such a system to
provide inhaler technique advice based on robust exist-
ing evidence,[57,58] but it is uncertain whether this
specific approach will engage people with asthma.
The EU-funded MyAirCoach project is an ambitious
collaborative initiative that aims to deliver an evidence
base for this challenging area. The ambition of
MyAirCoach is to integrate technology: ‘with a smart
sensing infrastructure and clinical prediction models in
order to provide personalised feedback to patients on
how to manage their condition in their home or at
work, without the need to have frequent face-to-face
contact with healthcare professionals in the hospital or
clinic.’[59] The initial phases of MyAirCoach have
focused on understanding end user preferences and
attitudes, to begin to build an interface that is intuitive
for patients of different ages and backgrounds, while
also increasing their involvement in the healthcare
process. MyAirCoach also aims to facilitate healthcare
professionals’ access to a detailed and accurate picture
of the patient’s health state when they are away from
the clinic environment. This will allow a more objective
assessment of an individual’s current status and the
evolution of their condition, and better inform treat-
ment decisions. Clinicians will soon have remote warn-
ing of individuals with high beta-agonist use and /or
low peak flow, with an early alert carrying the potential
for intervention to avert a serious adverse outcome.
Objective data from smart inhalers on adherence and
technique already informs the decision to step up treat-
ment in severe asthma centres (Refractory Asthma
Stratification Programme [RASP]-UK [60]). The bene-
fit to payors will be a move away from the inefficient
annual review of airways disease to a more persona-
lised, dynamic and responsive model with more effi-
cient and targeted use of face-to-face consultations,
offering the potential to reduce the number and dura-
tion of exacerbations and hospital admissions without
expanding the current staffing resource.
At the population level, integration of new data into
the EHR may also enable identification and monitoring
of sentinel networks. Using pollen allergy as an exam-
ple, the networks would include highly sensitised and
characterised patients with asthma and rhinitis whose
condition can be easily triggered by rising pollen
counts. By monitoring and identifying changes in con-
trol within sentinel groups it is feasible to forewarn the
wider geo-localised population of recommended man-
agement approaches (e.g. trigger avoidance and/or
pharmacological step up; see Figure 4).[56]
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An integrated EHR containing standard clinical infor-
mation from multiple healthcare records, new biomarker
results, and behavioural and contextual data from con-
nected devices remains the ultimate goal, a ‘big data’
scenario. This detailed description of an individual is
likely to be a better predictor of future risk of adverse
events, and of likely response to specified treatments. This
ambition is being supported at the European level
through the CONNECARE project which aims to
develop, deploy and evaluate an adaptive integrated care
system for chronic care management (including asthma
and COPD) that will provide decision support for the
adaptive management of personalised clinical pathways
and will deliver tools to monitor patients’ activities and
status, thus empowering them and providing them with
recommendations to self-manage their condition.[61]
Data quality and future proofing
We have presented the case and the potential of the
EHR, but for these remarkable opportunities to become
realities many significant practical challenges must be
overcome. A full discussion of this area is beyond the
scope of this review, but key aspects pertinent to EHR
include data quality especially input and coding, and
(from an emerging technologies perspective) data stan-
dards, visualisation, integration and analysis. The med-
ical workforce will also need to be trained to
understand, accept and utilise the opportunities offered
and to co-produce software and connected devices.
Quality data are critical to the effective realisation of
the care and resource efficiencies EHRs promise and to
the calibre of research they can sustain. Data quality
encapsulates a multitude of dimensions, among them:
specificity of coding; scope nature of variables (catego-
rical /continuous), completeness of coding; complete-
ness of data and, when using the data to inform CDSS,
the representativeness of the data.
Some of the issues around data quality can be illu-
strated through brief discussion of the role of the UK’s
Quality and Outcomes Framework (QOF) on primary
care EMRs in the UK. QOF was introduced in 2004 as
part of the General Medical Services (GMS) contract
for general practices [62] and governs reimbursement
to practices for the provision of ‘quality care’ against
certain outlined parameters. QOF incentivises practices
to record various care activities within the EHR to
ensure attainment of prescribed QOF criteria. In
obstructive airways disease, this includes spirometric
confirmation of COPD and performance of an annual
review for anyone with asthma or COPD (i.e. two
reviews for patients allocated a diagnostic code for
both conditions). The influence of QOF on the EMR
can be seen in terms of the more complete lung func-
tion records available for patients with a COPD since
2004 and (a degree of) ‘cleaning up’ of the diagnostic
coding of asthma and COPD. Yet it also drives data
collection around certain parameters (a ‘points for
prizes’ mentality) and does not extend to all manage-
ment aspects of all conditions. Still considering the UK,
there are issues around data completeness as primary
and secondary care EMRs remain largely discrete sys-
tems. Secondary care events are only captured in the
primary care EMR as a result of manual input by
general practitioners and are, as a result, systematically
under-recorded. Data linkage approaches using anon-
ymised patient identifiers to triangulate and integrate
different data sources (hospital episode statistics, pri-
mary care, mortality records, etc.) to provide a more
complete picture have achieved very limited success.
The situation, again, varies between countries.
In some parts of Sweden, primary and secondary care
use the same digital recording system, making it is possible
for healthcare professionals to access a more complete
record (including primary and secondary care data,
Figure 4. Examples of the MACVIA-ARIA Sentinel NetworK
(MASK) to guide implementation of management interventions
for patients with severe pollen allergies.[56] Reproduced with
permission from John Wiley and Sons.
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laboratory data, medication lists and X-rays), which offers
great benefit to clinical work. In several regions there is also
a central database for spirometry results with shared access
across primary and secondary care professionals. Swedish
national healthcare quality assessment involves remote
extraction and curation of certain parameters within dis-
ease-specific registers. These data are then used for research
and to provide feedback to healthcare professionals with
regards to benchmarking of their practice against national
guidelines, priorities and quality indicator attainment.[63]
At an international level, pooling national datasets can
power micro-stratification based on individual patient
characteristics compared to matched controls and assist
with the evaluation of incidence and prevalence of rare
events and diseases. The benefits of international data
linkage come with considerable challenges: navigating dif-
fering national legislations ondata usage, normalising data-
sets across core standardised variables (and units) and
aligning different coding systems (e.g. ICD-9 and 10,
Read codes, SNOMED, ICPC). Within the realms of what
is legally permissible, integration is feasible if supported by
application programming interfaces (APIs) and identifica-
tion of key common variables critical to meaningful out-
come evaluation, as demonstrated by the Uncovering and
Noting Long-term Outcomes in COPD to enhance
Knowledge (UNLOCK) Group.[64]
From an integrated EHR perspective, data from multi-
ple types of smart inhaler or other connected technologies
must be recorded following common definitions of core
characteristics (e.g. medication adherence, lung function,
control, exacerbations, healthcare resource utilisation).
The data transferred from the devices will need to use a
common API so that data can be pooled and integrated
across sources. It should also be secure in transit and in a
form that does not breach a patient’s wishes regarding
privacy (e.g. geolocalisation). Standardisation will be dif-
ficult to achieve in the early phase of adoption where
many small and medium enterprises are producing
devices and software, combined political pressures and
market forces should encourage longer-term planning by
developers with greater engagement with established
healthcare providers.
Barriers
The respiratory community has much to gain from the
implementation of electronic records, connected
devices, and biomarkers. However, any significant
change in clinical practice also carries risks of potential
harm and cost. These risks are amplified when there
are multiple aspects to the change, rapidly evolving
new technologies are involved, and there is a step
change in the amount of information available.
Figure 5 illustrates key potential issues: there are
already examples of problems such as relatively inaccu-
rate sensors,[65] misleading user [66] or clinician feed-
back [67] and some users disengaging from remote
Figure 5. Illustration of areas where caution is required in the uptake of emerging healthcare technology based solutions.
Data from connected devices may require specific smartphone software (1) which may not be compatible with all devices (2),
restricting treatment choice. Users may not enter symptom data regularly or accurately (3), and could be misled by feedback (4).
Sensors may not be reliable (5) or accurate (6). Data transfer into secure clinical networks is not straightforward (7), and it needs to
be correctly incorporated into individuals’ EHRs (8). Displaying large amounts of complex real-time data to inform clinical decision-
making is challenging (9). At all stages, there is the perceived risk of data being gathered by third parties (10).
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monitoring.[68] Additional problems arise from provi-
ders acquiring different hardware or software solutions
before interoperability standards are established.
Retrospective resolution of such issues is possible and
rewarding but time-consuming and costly: pro-active
collaborative planning is preferable.
The recent Wachter Review outlines core principles
for the transformation to a fully paperless healthcare
service.[69] Alongside this, interoperability issues are
beginning to be addressed by groups such as
INTEROPen [70] and HL7 which bring together suppli-
ers, providers and NHS digital information systems.
Further, the analysis and visualisation of these
new data streams will pose challenges for clinicians
coupled with a need to prevent information overload.
Simple measures such as assessing concordance with
inhaled steroids or simple track and trigger tools
(analogous to ward-based ‘early warning scores’) are
likely to be incorporated into practice in the near
future once initial rules are resolved. The visualisa-
tion of such trends is currently technically feasible,
but will also require standardisation. However,
devolving greater responsibility to supervised artifi-
cial intelligence systems that can process large-scale
parallel complex data (such as location) in near real-
time, challenges the current nature of clinical prac-
tice and notions of physician responsibility. Without
this change being properly managed, clinicians risk
being overwhelmed with the amount of data they
have to handle.[71]
Conclusions
The transition from paper to electronic recording of
medical data is progressing at pace, particularly
where there are/were incentives for adoption and
subsequent realisation of healthcare payment and
reimbursement through adoption and usage. With
the proliferation of EMRs comes complementary
opportunities for care, resource efficiencies and
clinical research. As we move forward, the major
investment in EHRs and new technologies will not
be in the hardware, but in change management as
healthcare professionals learn how to use these digi-
tal tools and their data effectively, and providers
restructure systems to cope with flexible, responsive,
and personalised care.
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